Human Immunodeficiency Viruses (HIV) Clinical Trials Market Expansion Outlook: $2.72 Billion by 2029 Forecast
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Predicted Market Size Trajectory For The Human Immunodeficiency Viruses (HIV) Clinical Trials Market From 2025 To 2034?
The human immunodeficiency viruses (HIV) clinical trials market size has shown significant expansion in recent years. It is projected to increase from $1.77 billion in 2024 to $1.94 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. This growth during the past period can be primarily linked to the increasing prevalence of drug-resistant human immunodeficiency viruses strains, a rising demand for personalized medicine in human immunodeficiency viruses care, an increasing emphasis on early diagnosis and treatment, a growing number of clinical research organizations, and greater awareness of human immunodeficiency viruses-related comorbidities.
The human immunodeficiency viruses (HIV) clinical trials market is anticipated to experience substantial expansion in the coming years. By 2029, this market is projected to reach $2.73 billion, demonstrating a compound annual growth rate (CAGR) of 9.0%. This anticipated growth during the forecast period is fueled by several factors, including the rising incidence of human immunodeficiency viruses infections, enhanced understanding of HIV prevention and management, wider acceptance of antiretroviral therapy, increased governmental financial backing for human immunodeficiency viruses research, and expanded investments within the biotechnology and pharmaceutical sectors. Key trends expected during this period encompass technologically-driven breakthroughs in HIV diagnostics, improvements in antiretroviral therapy (ART) formulations, progress in identifying biomarkers, the emergence of technology-enabled remote monitoring solutions, and the incorporation of digital health platforms.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28244&type=smp
What Are The Drivers Pushing New Developments In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
The human immunodeficiency virus (HIV) clinical trials market is poised for growth driven by the rising prevalence of HIV infections. HIV infections refer to a state where the HIV virus attacks and weakens the immune system, making individuals more prone to various infections and potentially leading to AIDS. The increase in HIV infections can largely be attributed to a lack of awareness regarding transmission, which leads to risky behaviors and delayed testing, thereby facilitating the virus’s spread. Human immunodeficiency virus (HIV) clinical trials assist patients with HIV infections by evaluating new drugs, vaccines, and treatment strategies designed to enhance prevention, manage the virus more effectively, and ultimately decrease disease progression and transmission. As an illustration, in August 2024, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, reported that an estimated 39.9 million individuals globally were living with HIV in 2023, consisting of 38.6 million adults and 1.4 million children, a higher figure compared to previous years. Therefore, the growing occurrence of human immunodeficiency virus (HIV) infections is a key driver for the expansion of the human immunodeficiency virus (HIV) clinical trials market.
What Are The Major Segments Identified In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
The human immunodeficiency viruses (HIV) clinical trials market covered in this report is segmented as
1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical
2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs
3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies
4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations
5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies
2) By Phase Ii: Dose-Finding Studies, Efficacy Studies
3) By Phase Iii: Pivotal Trials, Comparative Efficacy Studies
4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies
5) By Preclinical: In Vitro Studies, Animal Studies
What Key Innovation Trends Are Fueling Advancements In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?
Leading companies operating in the human immunodeficiency virus (HIV) clinical trials market are prioritizing the development of innovative solutions, such as HIV prevention injections, to boost treatment effectiveness and decrease transmission rates. An HIV prevention injection is a long-acting injectable medication administered periodically to prevent HIV infection in high-risk individuals by preventing the virus from establishing itself in the body. For example, in August 2025, Gilead Sciences Inc., a US-based pharmaceutical company, gained approval from the European Union for Yeytuo (lenacapavir) for the treatment of HIV. This is a twice-yearly injectable HIV prevention treatment that exhibits high efficacy, nearly 100% in clinical trials, significantly reducing the risk of sexually acquired HIV-1 infection. Its long-acting dosage regimen improves adherence and convenience when compared to daily oral PrEP, thereby addressing a major gap in HIV prevention. Designed for adults and adolescents at increased risk, this initiative aims to expand access and help reduce new HIV infections globally as part of comprehensive prevention strategies.
Which Global Market Leaders Are Shaping The Future Of The Human Immunodeficiency Viruses (HIV) Clinical Trials Sector?
Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio.
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Human Immunodeficiency Viruses (HIV) Clinical Trials Industry Expansion?
North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus (HIV) clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28244&type=smp
Browse Through More Reports Similar to the Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market 2025, By The Business Research Company
Human Immunodeficiency Virus Hiv Diagnosis Global Market Report 2025
Hiv Drug Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report
Antiviral Combination Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
